Open Access

Chromosome engineering of Escherichia coli for constitutive production of salvianic acid A

Microbial Cell Factories201716:84

DOI: 10.1186/s12934-017-0700-2

Received: 15 March 2017

Accepted: 10 May 2017

Published: 16 May 2017



Salvianic acid A (SAA), a valuable natural product from herbal plant Salvia miltiorrhiza, exhibits excellent antioxidant activities on food industries and efficacious therapeutic potential on cardiovascular diseases. Recently, production of SAA in engineered Escherichia coli was established via the artificial biosynthetic pathway of SAA on the multiple plasmids in our previous work. However, the plasmid-mediated system required to supplement expensive inducers and antibiotics during the fermentation process, restricting scale-up production of SAA. Microbial cell factory would be an attractive approach for constitutive production of SAA by chromosome engineering.


The limited enzymatic reactions in SAA biosynthetic pathway from glucose were grouped into three modules, which were sequentially integrated into chromosome of engineered E. coli by λ Red homologous recombination method. With starting strain E. coli BAK5, in which the ptsG, pykF, pykA, pheA and tyrR genes were previously deleted, chassis strain BAK11 was constructed for constitutive production of precursor l-tyrosine by replacing the 17.7-kb mao-paa cluster with module 1 (P lacUV5 -aroG fbr -tyrA fbr -aroE) and the lacI gene with module 2 (P trc -glk-tktA-ppsA). The synthetic 5tacs promoter demonstrated the optimal strength to drive the expression of hpaBC-d-ldh Y52A in module 3, which then was inserted at the position between nupG and speC on the chromosome of strain BAK11. The final strain BKD13 produced 5.6 g/L of SAA by fed-batch fermentation in 60 h from glucose without any antibiotics and inducers supplemented.


The plasmid-free and inducer-free strain for SAA production was developed by targeted integration of the constitutive expression of SAA biosynthetic genes into E. coli chromosome. Our work provides the industrial potential for constitutive production of SAA by the indel microbial cell factory and also sets an example of further producing other valuable natural and unnatural products.


Salvianic acid A Escherichia coli Constitutive promoter Metabolic engineering Synthetic biology Chromosomal engineering


Salvianic acid A (SAA, 3-(3′,4′-dihydroxyphenyl)-2-hydroxypropanoic acid), also called danshensu, is the major bioactive ingredient of traditional Chinese herb plant Salvia miltiorrhiza (danshen) which is widely used for the prevention and treatment of vascular diseases in clinic [1, 2]. SAA is well-known for its distinguished antioxidant capacity to scavenge the superoxide anion radicals and free hydroxyl radicals, which is even higher than vitamin C [3]. In recent years, SAA has attracted considerable attentions due to its various pharmacological activities, including inhibition of platelet activation and arterial thrombosis [4], alleviation of alcohol-induced acute liver damage [5] and myocardial ischemia injury [6]. Moreover, SAA derivatives, salvianolic acids B and A, and rosmarinic acid, show promising application in medicines and food industries. Salvianolic acid B has already been used to alleviate angina pectoris and treat coronary heart diseases in clinic [7]. Salvianolic acid A has been approved by China Food and Drug Administration (CFDA) into phase I clinical trial. Rosmarinic acid could be used for food preservation as a natural antioxidant to substitute synthetic antioxidant like butylated hydroxytoluene [8]. Notably, conjugates of SAA with cysteine show better vascular-protective effect than SAA [9].

Although SAA could be extracted from root of S. miltiorrhiza, tiny amount of SAA in roots (0.045%) restricts its application [10]. The chemical synthesis of SAA suffers from intractable enantioselectivities for large-scale production [11]. An alternative route for SAA production was developed previously in our laboratory via metabolic engineering of Escherichia coli [12, 13] (Fig. 1a). In order to intensify the availability of PEP, block the competitive biosynthesis of l-phenylalanine and eliminate the transcriptional repression of genes in l-tyrosine biosynthetic pathway, the ptsG, pykF, pykA, pheA and tyrR genes were deleted, and l-tyrosine overproducing strain BAK5 was obtained. For efficient production of SAA, strain BAK5 harbored three extra expression plasmids: middle-copy-number plasmid (30–40 copies) carrying module 1 (aroG fbr -tyrA fbr -aroE) and module 2 (ppsA-tktA-glk), middle-copy-number plasmid (~20 copies) carrying module 3 (hpaBC-d-ldh Y52A ), and low-copy-number plasmid carrying T7 RNA polymerase gene [12]. Despite this available alternative, SAA production by plasmid-mediated strain had serious drawbacks. Expensive isopropyl-β-d-thiogalactopyranoside (IPTG) was necessary to induce the expression of target genes. Additional antibiotics to maintain the genetic stability were harmful to cell growth and environmentally unfriendly [14]. Taken together, overexpressing target genes on multiple plasmids has become a barrier for industrial-scale production of natural product SAA.
Fig. 1

Chromosomal engineering for constitutive production of salvianic acid A (SAA) in E. coli. a The artificial synthetic pathway of SAA from glucose. b The targeted integration of three modules into chromosome of engineered strains. In-frame deletion of the ptsG, pykF, pykA, pheA and tyrR genes were not shown in chromosome of strain BAK5. 6‐P‐G 6‐phosphate‐glucose, 6‐P‐F 6‐phosphate‐fructose, E4P erythrose‐4‐phosphate, PEP phosphoenolpyruvate, PYR pyruvic acid, DAHP 3‐deoxy‐d‐arabino‐heptulosonate‐7‐phosphate, DHS 3‐dehydroshikimic acid, SHK shikimic acid, CHA chorismic acid, l -Phe l-phenylalanine, 4‐HPP 4‐hydroxyphenylpyruvic acid, l -Tyr l-tyrosine, DHPP 3,4-Dihydroxyphenylpyruvate, 4-HPL 4-Hydroxyphenyllactate, TyrR-tyr TyrR-tyrosine DNA-binding transcriptional repressor, SAA salvianic acid A

Synthetic biology and metabolic engineering are promising strategies to deal with those obstacles by reconstructing inducer-free and plasmid-free strains. The constitutive promoters, the core elements for metabolic engineering, have been paid more attention to allowing inducer-free and continuous gene expression as well as low production cost [15]. Native constitutive promoters have been widely employed for producing bio-based chemicals [1618] and natural products [1922] by tuning target gene expression in engineered yeasts. In E. coli, the conventional T7 promoter has always been used for heterologous protein expression by additional inducer IPTG, but the constitutive promoters showed better performance for production of natural and non-natural products, which are adapted to the growth of host cells. The native constitutive gap promoter was more suitable for the heterologous expression of the 4 cl and sts genes in E. coli than the inducible T7 promoter, resulting in high production of resveratrol [23]. The P L derivative promoters could constitutively drive target gene expression in E. coli to maximize the desired phenotypes and benefit for effective production of lycopene [24], 2,3-butanediol [25] and human growth hormone receptor antagonist [26]. In addition, chromosomal integration of the target gene would eliminate the use of plasmids in host cells and relieve the metabolic burden. Excellent examples were high-yielding production of artemisinic acid, a precursor of artemisinin, and lycopene in baking yeast [27, 28]. The plasmid-free E. coli strains could stablely produce astaxanthin [29], shikimic acid [30] and β-carotene [31].

In this study, E. coli BAK5 [12] was used as the start strain. Limited enzymatic reactions of SAA synthetic pathway from glucose in engineered E. coli were grouped into three modules as in previous work [12]. Modules 1 and 2 were integrated into the chromosome of strain BAK5, and strain BAK11 for overproducing l-tyrosine without any plasmids was constructed (Fig. 1b). The optimal promoter for driving module 3 was screened out by fine tuning constitutive expression, and integrated into chromosome of strain BAK11, a plasmid-free and inducer-free E. coli strain BKD13 for constitutive production of SAA was constructed (Fig. 1b). Finally, fed-batch fermentation was taken out and engineered strain BKD13 produced 5.6 g/L of SAA in 60 h. To our knowledge, this is the first report describing SAA production by engineered E. coli without addition of any inducers and antibiotics.


Bacterial strains, plasmids and reagents

The bacterial plasmids and strains used in this study were listed in Tables 1 and 2, respectively. All primers used in this study were summarized in Additional file 1: Table S1). E. coli DH5α was employed for all gene cloning work and E. coli BW25113 derivatives were used to construct SAA producing strains. The primers and long DNA fragments were synthesized by GENEWIZ (Suzhou, China). Methanol and acetate (HPLC grade) were purchased from Concord Tech (China). All other chemicals and reagents used in the experiment were of analytical grade commercially available. SAA (98% purity) was purchased from Xi’an Honson Biotechnology Company (China). l-tyrosine (99.9% purity) and l-dopa (99.9% purity) were purchased from Dingguo Biotech (China). DNA Polymerase of Phanta Super Fidelity and Taq for PCR were purchased from Vazyme (Nanjing, China). T4 DNA ligase and restriction endonucleases were purchased from Thermo Scientific (Beijing, China). The plasmids were constructed by ligating the PCR products and plasmids, which were all digested by the same restriction endonucleases. Successful recombinant plasmids were confirmed by colony PCR and DNA sequencing.
Table 1

Plasmids used in this study





FRT (FLP recognition target) sites; CmR



Red recombinase expression vector; AmpR



FLP expression vector; AmpR, CmR



p15A ori; CmR



pBldgbrick 1 with P lacUV5 -aroG fbr -tyrA fbr -aroE, P trc -ppsA-tktA-glk



pCDFDuet-1 with hpaBC and d-ldh Y52A



p15A ori; CmR

This study


pZL with fragment 1

This study


pZL with fragment 2

This study


pZL with P BBa-J23100 -hpaBC and P BBa-J23100 -d-ldh Y52A

This study


pZL with P tac -hpaBC and P tac -d-ldh Y52A

This study


pZL with P tac -hpaBC and P BBa-J23100 -d-ldh Y52A

This study


pZL with P BBa-J23100 -hpaBC and P tac -d-ldh Y52A

This study


pZL with fragment 3

This study


pZL7 with rrnB P1 promoter

This study


pZL with P 5tacs -hpaBC- d-ldh Y52A

This study


pZL with P rrnB P1 -hpaBC- d-ldh Y52A

This study

Table 2

Strains used in this study





BW25113 ΔptsG, ΔtyrR, ΔpykA, ΔpykF, ΔpheA



BAK5 Δmao-paa cluster::P lacUV5 -aroG fbr -tyrA fbr-aroE-Chl

This study


BAK5 Δmao-paa cluster::P lacUV5 -aroG fbr -tyrA fbr-aroE

This study


BAK10 ΔlacI::P trc -ppsA-tktA-glk-Chl

This study


BAK10 ΔlacI::P trc -ppsA-tktA-glk

This study


BAK5 with pYBH1, pYBT5 and pYBD4



BAK11 with pZL3

This study


BAK11 with pZL5

This study


BAK11 with pZL6

This study


BAK11 with pZL4

This study


BAK11 with pZL10

This study


BAK11 with pZL9

This study


BAK11 nupG::P5tacs -hpaBC-d-ldh Y52A -Chl

This study


BAK11 nupG::P5tacs -hpaBC-d-ldh Y52A

This study

Construction of SAA-producing expression vectors with constitutive promoters

Four constitutive promoters, P BBa-J23100 , P tac , P5tacs and P rrnB P1 , were used to construct expression vectors. Three fragments (F1, F2 and F3) containing multiple cloning sites, BBa-B0015 terminator were designed and synthesized to simplify the vector construction (Additional file 1: Table S2). In order to achieve the maximum translation level, the synthetic 5′-untranslated region (5′-UTR) sequences of the hpaBC and d-ldh Y52A genes were predicted by the UTR Designer ( and designed in primers hpaBC F and d-ldhY52A F directly. Plasmid pACYCDuet-1 was digested with ApaI and XhoI, and the fragment containing the p15A ori and CmR was served as the skeleton vector pZL.

To construct plasmids pZL3, 4, 5 and 6 for bicistron expression of the hpaBC and d-ldh Y52A genes, pZL ligated with fragment F1 containing two BBa-J23100 promoters and fragment F2 containing two tac promoters at ApaI/XhoI, respectively, generating pZL1 and pZL2. Then pZL1 and pZL2 ligated with the hpaBC gene at HindIII/SpeI and the d-ldh Y52A gene at EcoRI/BamHI, which were amplified from plasmid pYBD4 with primers hpaBC F/R and d-ldhY52A F/R, respectively, generating pZL3 and pZL4. The P BBa-J23100 -hpaBC of pZL3 was replaced with P tac -hpaBC of pZL4 at ApaI/SpeI to generate pZL5. The P BBa-J23100 -d-ldh Y52A of pZL3 was replaced with P tac -d-ldh Y52A of pZL4 at SpeI/BamHI to generate pZL6.

To construct plasmids pZL9 and pZL10 for expressing the hpaBC and d-ldh Y52A genes as one operon, pZL ligated with F3 containing the 5tacs promoter digested with ApaI/XhoI, generating pZL7. The rrnB P1 promoter cloned from BAK5 genome with primers rrnB F/R was inserted into pZL7 digested with ApaI/HindIII, generating plasmid pZL8. Then pZL7 and pZL8 ligated with the hpaBC and d-ldh Y52A genes, generating pZL9 and 10, respectively.

Modular integration into chromosome

The integration strains were derived from strain BAK5 by using the λ Red homologous recombination method [32]. Module 1 replaced the mao-paa cluster, and module 2 replaced the lacI gene. Module 3 was integrated at the locus between nupG and speC. The three recombinated fragments for targeted integration of corresponding modules (ydbL-PlacUV5-aroGfbr-tyrAfbr-aroE-Chl-ydbA for module 1, lacZ-Ptrc-ppsA-tktA-glk-Chl-mhpR for module 2, nupG-P5tacs-hpaBC-d-ldhY52A-Chl-speC for module 3) were constructed by overlapping extension PCR. Here, construction process for module 1 integrating fragment as example was demonstrated in Additional file 1: Figure S1. Module 1 (PlacUV5-aroGfbr-tyrAfbr-aroE) was amplified from pYBT5 employing primers M1 F/R. The ydbL fragment (500 bp upstream) and the ydbA fragment (500 bp downstream) as homologous arms were cloned from BAK5 genome with primers ydbL F/R and ydbA F/R, respectively. Plasmid pKD3 was used as a template to clone the chloramphenicol resistance cassette employing primers Chl F/R. The ydbL fragment and module 1 were assembled into the ydbL-M1 fragment by overlapping extension PCR, and the chloramphenicol resistance cassette and the speC fragment were assembled into the Chl-ydbA fragment. The final fragment ydbL-M1-Chl-ydbA was generated by combining fragments ydbL-M1 with Chl-ydbA, and then electrotransformed into strain BAK5 which contained plasmid pKD46. The positive clone was confirmed by PCR. Afterwards, the chloramphenicol resistance was eliminated with the help of plasmid pCP20, which was further verified by PCR, and the final strain BAK10 was obtained. The same procedure was performed for the integration of module 2 and module 3, respectively.

Fermentation media and cultivation conditions

Escherichia coli cells were cultivated in Luria broth (LB) for strain maintenance and seed preparation. Modified MOPS (morpholinepropanesulfonic acid) medium containing 1× MOPS minimal salt [33], yeast extract (1 g/L) and glucose (5 g/L) was used for the production of l-tyrosine. The cultivation was conducted at 37 °C and 220 rpm with 50 mL of modified MOPS medium in 250 mL of shake flasks for 24 h. YM9 medium contained glucose (5 g/L), Na2HPO4 (6 g/L), KH2PO4 (3 g/L), NH4Cl (1 g/L), NaCl (0.5 g/L), CaCl2 (17 mg/L), MgSO4 (58 mg/L) and yeast extract (1 g/L) was used for the production of SAA. The cultivation was conducted at 30 °C and 220 rpm with 50 mL of YM9 medium in 250 mL of shake flasks for 24 h. Appropriate antibiotics were added in medium when necessary: ampicillin (50 μg/mL) and chloramphenicol (20 μg/mL).

For bioreactor fermentation, seed culture (~400 mL) was inoculated into a 5 L fermenter (Bailun, Shanghai) containing 2.1 L fermentation medium, generating an initial OD600 of ~0.6. The fermentation medium contained glucose (7.5 g/L), Na2HPO4 (6.8 g/L), KH2PO4 (8.5 g/L), NH4Cl (3 g/L), NaCl (0.5 g/L), CaCl2·2H2O (0.07 g/L), MgSO4·7H2O (1 g/L), yeast extract (5 g/L). The pH was maintained at 7.0 by automatic addition of 10 M NaOH solution. The fermentation was performed at 30 °C with a 2.5 L/min airflow, and the dissolved oxygen (DO) level was controlled at 30% (v/v) by changing the agitation speed from 300 to 600 rpm automatically. The feeding solution contained 500 g/L glucose and 60 g/L yeast extract. Samples of fermentation broth were periodically withdrawn for analysis. The fermentation experiments were carried out in triplicates.

Analytical methods

Cell growth was determined by measuring the optical density (OD600) using a TU-1810 spectrophotometer. The concentration of residual glucose was quantified by a biosensor SBA-90 (Biology Institute of Shandong Academy of Sciences, China). To measure l-tyrosine, the sample was prepared as previously described [12]. To measure SAA and l-dopa, the broth sample was centrifuged directly and the supernatant was filtered through 0.22 μm syringe filter. All the metabolites were analyzed using Agilent 1200 HPLC system (LabAlliance Corp, USA) equipped with a C18 column (250 mm × 4.6 mm, 5 μm, Bonna-Agela, China) and a DAD detector (Agilent). The column temperature was set at 25 °C. 10 μL of sample was injected to the HPLC system for analysis. SAA, l-tyrosine and l-dopa were quantified at 281 nm. The mobile phase was methanol–water–acetate (20:80:0.1, v/v/v) and the flow rate was set at 1 mL/min. Identification and quantitation of compounds were verified by comparison of retention time and using a standard curve, which the R2 coefficient was higher than 0.99.

Results and discussion

Construction of plasmid-free chassis strain for constitutive production of precursor l-tyrosine

l-tyrosine is precursor for SAA biosynthesis (Fig. 1a). Accordingly, sufficient supplement of l-tyrosine facilitates the production of SAA. The biosynthetic pathway of l-tyrosine is tightly regulated by l-tyrosine feedback and transcription repression [34]. A variety of metabolic engineering approaches have been use to improve l-tyrosine production by deleting repressing gene tyrR and overexpressing feedback-resistant genes aroG fbr and tyrA fbr , and other genes of limited steps on plasmids [35, 36]. Plasmid-mediated l-tyrosine producer strains needed the addition of corresponding antibiotics and IPTG to control gene overexpression of interest [3739]. Although feedback-resistant genes aroG fbr and tyrA fbr were integrated into the tyrR locus of E. coli chromosome, inducer IPTG was required for l-tyrosine fermentation as the T7 promotor was used [40].

In previous work, we constructed an engineered l-tyrosine overproducing E. coli strain BAK5 with a plasmid overexpressing module 1 and module 2. Module 1 containing aroG fbr -tyrA fbr -aroE and module 2 consisting of ppsA-tktA-glk were driven by the lacUV5 and trc promoters (Fig. 1b), respectively. In order to eliminate the drawbacks of plasmid-mediated system, module 1 and module 2 were integrated into the chromosome of strain BAK5 for constitutive production of precursor l-tyrosine. The mao-paa cluster involved in the degradation of aromatic acids [41] was chosen as the target site to integrate module 1. The fragment ydbL-PlacUV5-aroGfbr-tyrAfbr-aroE-Chl-ydbA was assembled by overlapping extension PCR, and replaced the long mao-paa cluster (~17.7 kb) on chromosome of strain BAK5 by λ Red homologous recombination method [32] as described in section of “Methods”. Successful replacement of the mao-paa cluster with module 1 was verified by the colony PCR, and strain BAK10 was generated (Fig. 2a).
Fig. 2

Construction of plasmid-free chassis strain BAK11 to produce l-tyrosine constitutively. a Replacement of the mao-paa cluster with module 1. Lane 1 The paaZ gene of the mao-paa cluster in strain BAK5 with primers paaZ F/R; lane 2 ydbL-M1-Chl-ydbA fragment in strain BAK10-1 with primers ydbL F and ydbA R; lane 3 ydbL-M1-ydbA fragment in strain BAK10 with primers ydbL F and ydbA R; M: DNA marker. b Cell growth and l-tyrosine production of strains BAK5 and BAK10. 0.1 mM IPTG was added into the medium when needed. c Replacement of the lacI gene with module 2. Lane 1 ydbL-lacI-ydbA in strain BAK10; lane 2 ydbL-M2-Chl-ydbA fragment in strain BAK11-1; lane 3 ydbL-M2-ydbA fragment in strain BAK11; primers lacZ F and mhpR R were used for all PCR verification. M: DNA marker. d Cell growth and l-tyrosine production of strain BAK11. 0.1 mM IPTG was added into the medium when needed

In order to test integrative effect of module 1 on the production of l-tyrosine, the shake fermentation was carried out. As shown in Fig. 2b, l-tyrosine titer of strain BAK10 was 320.6 mg/L after 24 h of cultivation without IPTG induced, increasing 31.8% than that of strain BAK5. When inducer IPTG (0.1 M) was added into fermentation medium, the production of l-tyrosine had a 22.1% increment, indicating that the expression of module 1 was partially repressed by the negative regulatory gene lacI due to the existence of lacO in lacUV5 promoter region of module 1, we speculated that deleting lacI gene would further improve the production of l-tyrosine as well as eliminate the supplementation of inducer IPTG. Thus, we replaced lacI gene with module 2, and generated strain BAK11 (Fig. 2c). The l-tyrosine titer of BAK11 was 401.5 mg/L without the induction of IPTG (Fig. 2d), increasing 65.1 and 25.2% than those of strains BAK5 and BAK10, respectively. We also investigated whether IPTG could still regulate l-tyrosine production in strain BAK11. After induction with additional IPTG, l-tyrosine production of strain BAK11 was slightly decreased, along with the inhibition of cell growth (Fig. 2d), which might be resulted from the cellular toxicity of inducer IPTG [42]. Deletion of lacI gene completely eliminated the repression of LacI, and strain BAK11 constitutively produced precursor l-tyrosine without IPTG induction.

Screening promoter for constitutive expression of hpaBC and d-ldh Y52A to produce SAA

In the downstream of artificial biosynthetic pathway of SAA, module 3 contains the hpaBC and d-ldh Y52A genes, which code 4-hydroxyphenylacetate 3-hydroxylase and d-lactate dehydrogenase, respectively, and catalyze the reactions of 4HPP to SAA via two putative routes (Fig. 1a). To construct inducer-free SAA producing strain, promoters for the constitutive expression of the hpaBC and d-ldh Y52A genes were considered. The constitutive promoter BBa-J23100 has the strongest strength among BBa series of promoters in the Anderson promoter library (Registry of Standard Biological Parts,, and has been used to metabolically engineer E. coli for the constitutive production of l-tyrosine [43], butanol [44] and cadaverine [45]. In addition, hybrid tac promoter, derived from the trp and lacUV5 promoters, is well-known for the 2–7 folds higher strength than the parent promoters [46]. The tac promoter has been popularly employed in metabolic engineering [47, 48]. Thus, two strong constitutive promoters BBa-J23100 and tac were chosen for expression of the hpaBC and d-ldh Y52A genes as bicistron. Moreover, according to the N-terminal coding sequences of the hpaBC and d-ldh Y52A genes, 25-bp sequences of 5′-UTR were designed to achieve the the maximum translation level using UTR Designer [49]. The BBa-J23100 and tac promoters followed by the 5′-UTR were put in the front of the hpaBC and d-ldh Y52A genes, and four expression plasmids were generated (Additional file 1: Figure S2), after being introduced into strain BAK11, respectively, strains BKD7, BKD8, BKD9 and BKD10 were constructed.

To test expression efficiency of the hpaBC and d-ldh Y52A genes under the control of the BBa-J23100 and tac promoters, the production of SAA in fermentation broth was analyzed by HPLC (Additional file 1: Figure S3). As shown in Fig. 3a, among four expression patterns, the BBa-J23100 promoter in strain BKD7 gave the lowest titer of SAA (260.4 mg/L), while the tac promoter in strain BKD10 made the highest titer of SAA (409.5 mg/L), the combinations of the BBa-J23100 and tac promoters led to the moderate production of SAA. Notably, the broth turned brown or dark after 30 h fermentation. We suspected that the intermediate l-dopa could be accumulated from l-tyrosine and further converted into melanin by HpaBC [50]. As shown in Fig. 3a, l-dopa and l-tyrosine were detected in broth of four strains BKD7, BKD8, BKD9 and BKD10, and the higher accumulation of l-dopa and l-tyrosine, the lower production of SAA, indicating that the expression of the hpaBC and d-ldh Y52A genes driven by either the tac or BBa-J23100 promoter was inefficient for SAA production.
Fig. 3

Screening optimal promoter for constitutive expression of hpaBC and d-ldh Y52A for production of SAA. a The hpaBC and d-ldh Y52A were expressed as bicistron under the control of the tac and BBa-J23100 promoters. b hpaBC-d-ldh Y52A was expressed as one operon under the control of the 5tacs and rrnB P1 promoters, respectively

The rrnB P1 promoter was considered as a super constitutive promoter composing of a core promoter, a cis-acting DNA sequence and a trans-acting transcription factor-binding site, and has a major role in high-level synthesis of rRNA during exponential growth of E. coli cells [51]. Although the tac promoter is stronger than the BBa-J23100 promoter, one copy tac promoter might not be enough to express target genes for SAA production (Fig. 3a). The tandem repetitive promoter was more powerful than unrepetitive one for gene expression [52]. Five repetitive tac core promoter had suitable strength for transcription control and allowed high production of polyhydroxybutyrate in E. coli [53]. Here, the synthetic 5 × tac (designated as 5tacs) and rnnB P1 promoters were employed to drive expression of the hpaBC-d-ldh Y52A as monocistron operon (Additional file 1: Figure S2). As shown in Fig. 3b, strain BKD12 (with P5tacs ) produced 492.2 mg/L of SAA, 1.2-fold and 1.5-fold higher than strains BKD10 and BKD11 (with P rrnB P1 , 198.5 mg/L), respectively. We noticed that broth of strain BKD11 turned brown at 27 h fermentation, while broth of strain BKD12 did not. Interestingly, intermediates l-tyrosine (76.1 mg/L) and l-dopa (24.5 mg/L) were detected in broth of strain BKD11, but not in broth of strain BKD12, consistent without the observation of brown color. It indicated that the hpaBC-d-ldh Y52A under the control of the 5tacs promoter could completely convert l-tyrosine to SAA.

Chromosomal integration of module 3 for plasmid-free production of SAA

In order to construct plasmid-free strain, chromosomal integration of module 3 was further adopted. The expression cassette of P 5tacs -hpaBC- d-ldh Y52A in module 3 was integrated at the position between nupG and speC, which was demonstrated to be the most transcriptionally active for the expression of inserted gene [54], and then plasmid-free strain BKD13 was constructed (Fig. 4a).
Fig. 4

Construction of plasmid-free and inducer-free strain BKD13 for constitutive production of SAA. a Integration of module 3 into the locus between nupG and speC. Lane 1 nupG-speC fragment in strain BAK10; lane 2 nupG-M3-Chl-speC fragment in strain BAK11-1; lane 3 nupG-M3-speC fragment in strain BAK11; primers nupG F and speC R were used for all PCR verification. M: DNA marker. b The OD600 and titer of BKD13 with different initial glucose concentration. c Fed‐batch fermentation of BKD13 with glucose in shake flasks

To estimate the constitutive production behavior of engineered strain BKD13, preliminary fermentation was conducted in shake flasks with different concentrations of the initial glucose. As shown in Fig. 4b, 86.2 mg/L of SAA was obtained with 5 g/L of glucose, and 45.2 mg/L of l-tyrosine was accumulated in broth (Fig. 4b). With 7.5 g/L of the initial glucose, the SAA titer was increased to 120.5 mg/L and l-tyrosine titer was decreased to 21.3 mg/L, while SAA was decreased and l-tyrosine was increased with higher initial glucose (10 g/L) (Fig. 4b). However, no l-dopa was detected in broth.

In order to testify the potential of strain BKD13 for SAA production, the fed-batch fermentation of SAA was also carried out in shake flasks. As shown in Fig. 4c, with feeding glucose, the cell growth of strain BKD13 entered the stationary phase at 36 h and the SAA production was gradually accumulated to 620.15 mg/L at 48 h. Additionally, there were minor amounts of l-tyrosine (6.5 mg/L) and l-dopa (2.9 mg/L) in fermentation broth. The results indicated that the chromosomal integration of module 3 was efficient to produce SAA.

Fed‐batch fermentation for constitutive production of SAA in 5 L bioreactor

To evaluate the performance of plasmid-free and inducer-free SAA producing strain BKD13, the fed-batch fermentation was further carried out in a 5 L bioreactor. Based on concentration of residual glucose, feeding solution was added into the bioreactor to maintain it lower than 1.0 g/L. As shown in Fig. 5, during the fermentation process, the consumption of glucose was used for cell growth as well as for SAA biosynthesis, thus, the production of SAA coupled with the formation of biomass [55]. The final titer of 5.6 g/L SAA with the maximal biomass at OD600 ~ 86 was achieved at 60 h. Small amount of precursor l-tyrosine accumulated in the early stage of the fermentation and completely converted into SAA after 51 h, while tiny amount of l-dopa (5.5 mg/L) was detected only before 36 h, and the fermentation broth had never become brown or dark. These results indicated that the plasmid-free and inducer-free strain BKD13 could constitutively produce SAA from glucose. We previously constructed a plasmid-mediated strain BKD5, which produced 7.1 g/L of SAA and accumulated 53.8 mg/L of l-tyrosine in 70 h [12]. Compared to strain BKD5, strain BKD13 seems more efficient for the conversion of l-tyrosine precursor to SAA since no l-tyrosine was detected at the end of fermentation. However, cell growth of strain BKD13 was faster than that of strain BKD5 (OD600 ~ 4.0), which might lead to lower titer of SAA. Additionally, one copy of SAA synthetic genes in the chromosome of strain BKD13 might not be sufficient to utilize the central carbon metabolites to synthesize SAA. Amplification of integrated SAA synthetic genes [56] and optimization of fermentation process would further improve SAA production of strain BKD13.
Fig. 5

Fed‐batch fermentation of BKD13 with glucose in 5 L bioreactor


In this paper, we developed a constitutive SAA-overproducing E. coli strain by chromosomal engineering to overcome the drawbacks of plasmid-mediated expression systems. In order to streamline metabolic flux towards precursor l-tyrosine from glucose and eliminate the repression regulation of LacI, module 1 (P lacUV5 -aroG fbr -tyrA fbr -aroE) replaced mao-paa cluster of 17.7 kb and module 2 (P trc -ppsA-tktA-glk) replaced lacI gene in strain BAK5 by targeted integration and deletion. Furthermore, we screened the synthetic promoter 5tacs driving the expression of module 3 (hpaBC-d-ldh Y52A ) in one operon, which was further inserted at the position between nupG and speC. The plasmid-free and inducer-free E. coli strain BKD13 produced 5.6 g/L SAA from glucose at 60 h in a 5L fed-batch fermentation. Our work showed the opportunities for industrial production of SAA and its derivatives, like rosmarinic acid and salvianolic acids, as a good example without additional antibiotics nor inducers for engineered microbial fermentation.



salvianic acid A






4‐hydroxyphenylpyruvic acid


5′-untranslated region


4-hydroxyphenylacetate 3-hydroxylase

d-ldh Y52A

d-lactate dehydrogenase (Tyr 52 to Ala)


Authors’ contributions

LZ and GRZ designed research and experiments. LZ, QD and HYW carried out the experiments. LZ, ZNL and GZJ carried out the metabolite analysis and data processing. LZ, GZJ, ZNL and GRZ wrote the manuscript. All authors read and approved the final manuscript.


The authors are grateful for the financial support from the National Natural Science foundation of China (31570087, 21621004), the National High-Tech R&D Program of China (2012AA02A701), and the National Basic Research Program of China (2011CBA00800).

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The material and data supporting their findings can be found in the main paper and the additional file.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University
Key Laboratory of Systems Bioengineering (Ministry of Education), Tianjin University
SynBio Research Platform, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin)
College of Chemical and Biological Engineering, Zhejiang University
Yangtze River Pharmaceutical Group Co, Ltd.


  1. Zhao GR, Xiang ZJ, Ye TX, Juan YJ, Guo ZX. Antioxidant activities of Salvia miltiorrhiza and Panax notoginseng. Food Chem. 2006;99(4):767–74.View ArticleGoogle Scholar
  2. Ling S, Luo R, Dai A, Guo Z, Guo R, Komesaroff PA. A pharmaceutical preparation of Salvia miltiorrhiza protects cardiac myocytes from tumor necrosis factor-induced apoptosis and reduces angiotensin II-stimulated collagen synthesis in fibroblasts. Phytomedicine. 2009;16(1):56.View ArticleGoogle Scholar
  3. Zhao GR, Zhang HM, Ye TX, Xiang ZJ, Yuan YJ, Guo ZX, Zhao LB. Characterization of the radical scavenging and antioxidant activities of danshensu and salvianolic acid B. Food Chem Toxicol. 2008;46(1):73–81.View ArticleGoogle Scholar
  4. Huang ZS, Zeng CL, Zhu LJ, Jiang L, Li N, Hu H. Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase. J Thromb Haemost. 2010;8(6):1383–93.View ArticleGoogle Scholar
  5. Yang Y, Han Z, Wang Y, Wang L, Pan S, Liang S, Wang S. Plasma metabonomic analysis reveals the effects of salvianic acid on alleviating acute alcoholic liver damage. RSC Adv. 2015;5(46):36732–41.View ArticleGoogle Scholar
  6. Song Q, Chu X, Zhang X, Bao Y, Zhang Y, Guo H, Liu Y, Liu H, Zhang J, Zhang Y. Mechanisms underlying the cardioprotective effect of salvianic acid A against isoproterenol-induced myocardial ischemia injury in rats: possible involvement of L-type calcium channels and myocardial contractility. J Ethnopharmacol. 2016;189:157–64.View ArticleGoogle Scholar
  7. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2006;45(12):1345–59.View ArticleGoogle Scholar
  8. Erkan N, Ayranci G, Ayranci E. Antioxidant activities of rosemary (Rosmarinus Officinalis L.) extract, blackseed (Nigella sativa L.) essential oil, carnosic acid, rosmarinic acid and sesamol. Food Chem. 2008;110(1):76.View ArticleGoogle Scholar
  9. Pan LL, Wang J, Jia YL, Zheng HM, Wang Y, Zhu YZ. Asymmetric synthesis and evaluation of danshensu–cysteine conjugates as novel potential anti-apoptotic drug candidates. Int J Mol Sci. 2015;16(1):628–44.View ArticleGoogle Scholar
  10. Lam FF, Yeung JH, Chan KM, Or PM. Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels. Vasc Pharmacol. 2007;46(4):271–7.View ArticleGoogle Scholar
  11. Sayyed IA, Sudalai A. Asymmetric synthesis of l-DOPA and (R)-selegiline via, OsO4-catalyzed asymmetric dihydroxylation. Tetrahedron: Asymmetry. 2004;15(19):3111–6.View ArticleGoogle Scholar
  12. Yao YF, Wang CS, Qiao J, Zhao GR. Metabolic engineering of Escherichia coli for production of salvianic acid A via an artificial biosynthetic pathway. Metab Eng. 2013;19(5):79.View ArticleGoogle Scholar
  13. Bai CL, Zhao GR. Separation of salvianic acid A from the fermentation broth of engineered Escherichia coli using macroporous resins. J Sep Sci. 2015;38(16):2833–40.View ArticleGoogle Scholar
  14. Friehs K. Plasmid copy number and plasmid stability. Adv Biochem Eng Biot. 2004;86:47–82.Google Scholar
  15. Blazeck J, Alper HS. Promoter engineering: recent advances in controlling transcription at the most fundamental level. Biotechnol J. 2013;8(1):46.View ArticleGoogle Scholar
  16. Matsuda F, Ishii J, Kondo T, Ida K, Tezuka H, Kondo A. Increased isobutanol production in Saccharomyces cerevisiae by eliminating competing pathways and resolving cofactor imbalance. Microb Cell Fact. 2013;12(1):1–11.View ArticleGoogle Scholar
  17. Jong BWD, Shi S, Siewers V, Nielsen J. Improved production of fatty acid ethyl esters in Saccharomyces cerevisiae through up-regulation of the ethanol degradation pathway and expression of the heterologous phosphoketolase pathway. Microb Cell Fact. 2014;13(1):39.View ArticleGoogle Scholar
  18. Borodina I, Kildegaard KR, Jensen NB, Blicher TH, Maury J, Sherstyk S, Schneider K, Lamosa P, Herrgård MJ, Rosenstand I. Establishing a synthetic pathway for high-level production of 3-hydroxypropionic acid in Saccharomyces cerevisiae via β-alanine. Metab Eng. 2015;27:57–64.View ArticleGoogle Scholar
  19. Sun J, Shao Z, Zhao H, Nair N, Wen F, Xu JH, Zhao H. Cloning and characterization of a panel of constitutive promoters for applications in pathway engineering in Saccharomyces cerevisiae. Biotechnol Bioeng. 2012;109(8):2082.View ArticleGoogle Scholar
  20. Dai Z, Liu Y, Zhang X, Shi M, Wang B, Wang D, Huang L, Zhang X. Metabolic engineering of Saccharomyces cerevisiae for production of ginsenosides. Metab Eng. 2013;20(5):146–56.View ArticleGoogle Scholar
  21. Galanie S, Smolke CD. Optimization of yeast-based production of medicinal protoberberine alkaloids. Microb Cell Fact. 2015;14(1):144.View ArticleGoogle Scholar
  22. Brown S, Clastre M, Courdavault V, O’Connor SE. De novo production of the plant-derived alkaloid strictosidine in yeast. Proc Natl Acad Sci USA. 2015;112(11):3205.View ArticleGoogle Scholar
  23. Lim CG, Fowler ZL, Hueller T, Schaffer S, Koffas MAG. High-yield resveratrol production in engineered Escherichia coli. Appl Environ Microbiol. 2011;77(10):3451–60.View ArticleGoogle Scholar
  24. Alper H, Fischer C, Nevoigt E, Stephanopoulos G. Tuning genetic control through promoter engineering. Proc Natl Acad Sci USA. 2005;102(36):12678–83.View ArticleGoogle Scholar
  25. Tong YJ, Ji XJ, Shen MQ, Liu LG, Nie ZK, Huang H. Constructing a synthetic constitutive metabolic pathway in Escherichia coli for (R, R)-2,3-butanediol production. Appl Microbiol Biotechnol. 2016;100(2):637.View ArticleGoogle Scholar
  26. Menezes AC, Suzuki MF, Oliveira JE, Ribela MT, Furigo IC Jr, Donato J, Bartolini P, Soares CR. Expression, purification and characterization of the authentic form of human growth hormone receptor antagonist G120R-hGH obtained in Escherichia coli periplasmic space. Protein Expr Purif. 2016;131:91.View ArticleGoogle Scholar
  27. Paddon CJ, Westfall PJ, Pitera DJ, Benjamin K, Fisher K, Mcphee D, Leavell MD, Tai A, Main A, Eng D. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature. 2013;496(7446):528–32.View ArticleGoogle Scholar
  28. Chen Y, Xiao W, Wang Y, Liu H, Li X, Yuan Y. Lycopene overproduction in Saccharomyces cerevisiae through combining pathway engineering with host engineering. Microb Cell Fact. 2016;15(1):1–13.View ArticleGoogle Scholar
  29. Lemuth K, Steuer K, Albermann C. Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin. Microb Cell Fact. 2011;10(1):1–12.View ArticleGoogle Scholar
  30. Cui YY, Chen L, Zhang YY, Jian H, Liu JZ. Production of shikimic acid from Escherichia coli through chemically inducible chromosomal evolution and cofactor metabolic engineering. Microb Cell Fact. 2014;13(1):21.View ArticleGoogle Scholar
  31. Li Y, Lin Z, Huang C, Zhang Y, Wang Z, Tang YJ, Chen T, Zhao X. Metabolic engineering of Escherichia coli using CRISPR-Cas9 meditated genome editing. Metab Eng. 2015;31:13–21.View ArticleGoogle Scholar
  32. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA. 2000;97(12):6640–5.View ArticleGoogle Scholar
  33. Neidhardt FC, Bloch PL, Smith DF. Culture medium for enterobacteria. J Bacteriol. 1974;119(3):736–47.Google Scholar
  34. Gosset G. Production of aromatic compounds in bacteria. Curr Opin Biotechnol. 2009;20(20):651–8.View ArticleGoogle Scholar
  35. Patnaik R, Zolandz RR, Green DA, Kraynie DF. l-Tyrosine production by recombinant Escherichia coli: fermentation optimization and recovery. Biotechnol Bioeng. 2008;99(4):741–52.View ArticleGoogle Scholar
  36. Rodriguez A, Martínez JA, Flores N, Escalante A, Gosset G, Bolivar F. Engineering Escherichia coli to overproduce aromatic amino acids and derived compounds. Microb Cell Fact. 2014;13(1):126.Google Scholar
  37. Lütkeeversloh T, Stephanopoulos G. Combinatorial pathway analysis for improved l-tyrosine production in Escherichia coli: identification of enzymatic bottlenecks by systematic gene overexpression. Metab Eng. 2008;10(2):69–77.View ArticleGoogle Scholar
  38. Santos CN, Xiao W, Stephanopoulos G. Rational, combinatorial, and genomic approaches for engineering l-tyrosine production in Escherichia coli. Proc Natl Acad Sci USA. 2012;109(34):13538–43.View ArticleGoogle Scholar
  39. Juminaga D, Baidoo EE, Reddingjohanson AM, Batth TS, Burd H, Mukhopadhyay A, Petzold CJ, Keasling JD. Modular engineering of l-tyrosine production in Escherichia coli. Appl Environ Microbiol. 2012;78(1):89–98.View ArticleGoogle Scholar
  40. Kang SY, Choi O, Lee JK, Ahn JO, Ahn JS, Hwang BY, Hong YS. Artificial de novo biosynthesis of hydroxystyrene derivatives in a tyrosine overproducing Escherichia coli strain. Microb Cell Fact. 2015;14(1):78.View ArticleGoogle Scholar
  41. Díaz E, Ferrández A, Prieto MA, García JL. Biodegradation of aromatic compounds by Escherichia coli. Microbiol Mol Biol Rev. 2001;65(65):523–69.View ArticleGoogle Scholar
  42. Dvorak P, Chrast L, Nikel PI, Fedr R, Soucek K, Sedlackova M, Chaloupkova R, Lorenzo VD, Prokop Z, Damborsky J. Exacerbation of substrate toxicity by IPTG in Escherichia coli BL21(DE3) carrying a synthetic metabolic pathway. Microb Cell Fact. 2015;14(1):201.View ArticleGoogle Scholar
  43. Kim SC, Min BE, Hwang HG, Sang WS, Jung GY. Pathway optimization by re-design of untranslated regions for l-tyrosine production in Escherichia coli. Sci Rep. 2014;5(1):13853.Google Scholar
  44. Lim JH, Seo SW, Kim SY, Jung GY. Model-driven rebalancing of the intracellular redox state for optimization of a heterologous n-butanol pathway in Escherichia coli. Metab Eng. 2013;20(5):56–62.View ArticleGoogle Scholar
  45. Kwak DH, Lim HG, Yang J, Seo SW, Jung GY. Synthetic redesign of Escherichia coli for cadaverine production from galactose. Biotechnol Biofuels. 2017;10(1):20.View ArticleGoogle Scholar
  46. Boer HAD, Comstock LJ, Vasser M. The tac promoter: a functional hybrid derived from the trp and lac promoters. Proc Natl Acad Sci USA. 1983;80(1):21–5.View ArticleGoogle Scholar
  47. Lu W, Shi Y, He S, Fei Y, Yu K, Yu H. Enhanced production of CoQ 10 by constitutive overexpression of 3-demethyl ubiquinone-9 3-methyltransferase under tac promoter in Rhodobacter sphaeroides. Biochem Eng J. 2013;72:42–7.View ArticleGoogle Scholar
  48. Aghaabdollahian S, Rabbani M, Ghaedi K. Sadeghi HMM. Molecular cloning of Reteplase and its expression in E. coli using tac promoter. Adv Biomed Res. 2014;3:190.View ArticleGoogle Scholar
  49. Seo SW, Yang JS, Kim I, Yang J, Min BE, Kim S, Jung GY. Predictive design of mRNA translation initiation region to control prokaryotic translation efficiency. Metab Eng. 2013;15(1):67.View ArticleGoogle Scholar
  50. Muñoz AJ, Hernández-Chávez G, Anda RD, Martínez A, Bolívar F, Gosset G. Metabolic engineering of l-3,4-dihydroxyphenylalanine (l-DOPA) synthesis from glucose. J Ind Microbiol Biotechnol. 2011;38(11):1845–52.View ArticleGoogle Scholar
  51. Maeda M, Shimada T, Ishihama A. Strength and regulation of seven rRNA promoters in Escherichia coli. PLoS ONE. 2015;10(12):e0144697.View ArticleGoogle Scholar
  52. Wu H, Wang H, Chen J, Chen GQ. Effects of cascaded vgb promoters on poly(hydroxybutyrate) (PHB) synthesis by recombinant Escherichia coli grown micro-aerobically. Appl Microbiol Biotechnol. 2014;98(24):10013–21.View ArticleGoogle Scholar
  53. Li M, Wang J, Geng Y, Li Y, Qian W, Liang Q, Qi Q. A strategy of gene overexpression based on tandem repetitive promoters in Escherichia coli. Microb Cell Fact. 2012;11(1):19.View ArticleGoogle Scholar
  54. Bryant JA, Sellars LE, Busby SJ, Lee DJ. Chromosome position effects on gene expression in Escherichia coli K-12. Nucleic Acids Res. 2014;42(18):11383–92.View ArticleGoogle Scholar
  55. De Hollander JA. Kinetics of microbial product formation and its consequences for the optimization of fermentation processes. Antonie Van Leeuwenhoek. 1993;63(3):375.View ArticleGoogle Scholar
  56. Tyo KEJ, Ajikumar PK, Stephanopoulos G. Stabilized gene duplication enables long-term selection-free heterologous pathway expression. Nat Biotechnol. 2009;27(8):760–5.View ArticleGoogle Scholar


© The Author(s) 2017